Alpha-ketoglutarate's evidence tier has been stuck at Emerging on a single uncontrolled trial. A placebo-controlled RCT is what would actually move it — here's what that trial is designed to answer.
Alpha-ketoglutarate's most-cited human evidence — the TruAge trial (Demidenko et al., 2023) — reported an 8-year reduction in epigenetic age after 7 months of supplementation. It is also uncontrolled: no placebo arm, no randomization, self-selected participants. That design cannot distinguish a true treatment effect from regression to the mean, seasonal variation, or assay drift.
This is precisely the gap a properly randomized, placebo-controlled trial closes. That trial, referred to in the field as ABLE, is designed to test alpha-ketoglutarate against placebo using validated epigenetic clocks (GrimAge and/or PhenoAge) as primary endpoints, with a control arm to isolate the actual treatment effect from the confounds that limit the TruAge data.
A positive, well-powered ABLE result — showing a significant epigenetic-age reduction versus placebo, replicating the direction (if not necessarily the magnitude) of the TruAge signal — would be the first placebo-controlled human evidence for alpha-ketoglutarate and would meaningfully support upgrading its evidence tier, particularly if paired with a functional or biomarker secondary endpoint.
A null result would not necessarily debunk alpha-ketoglutarate outright — it would specifically call into question whether the uncontrolled TruAge signal reflected a true treatment effect or the confounds inherent to its design, which is exactly the question worth resolving either way.
ABLE is part of a broader pattern of longevity trials increasingly using epigenetic clocks as primary or secondary endpoints, given the impracticality of waiting decades for mortality data. This is a reasonable pragmatic choice, but it inherits an unresolved question discussed elsewhere on Geroevidence: epigenetic clocks are validated as population-level mortality predictors, but it has not been demonstrated that interventions which shift clock scores thereby extend lifespan. Any ABLE result should be read with that caveat in mind, regardless of direction.
Alpha-ketoglutarate's current Emerging tier rests on evidence with a specific, well-understood limitation — no control arm. The ABLE trial is designed to directly address that limitation. Until it reports, the honest position is that alpha-ketoglutarate has a real mechanistic case and animal data, but human efficacy remains genuinely unconfirmed by controlled evidence.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.